Preclinical and Clinical Evaluation of Magnetic-Activated Cell Separation Technology for CTC Isolation in Breast Cancer.
breast cancer
circulating tumor cells
liquid biopsy
magnetic-activated cell separation
morphology
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
04
2020
accepted:
25
08
2020
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
13
10
2020
Statut:
epublish
Résumé
Circulating tumor cell (CTC) count is an independent prognostic factor in early breast cancer. CTCs can be found in the blood of 20% of patients prior to neoadjuvant therapy. We aimed to assess the suitability of magnetic-activated cell separation (MACS) technology for isolation and cytological characterization of CTCs. In the preclinical part of the study, cell lines were spiked into buffy coat samples derived from healthy donors, and isolated using MACS. Breast cancer cells with preserved cell morphology were successfully isolated. In the clinical part, blood for CTC isolation was drawn from 44 patients with early and locally advanced breast cancer prior to neoadjuvant chemotherapy. Standard Giemsa, Papanicolaou and pancytokeratin staining was applied. 2.3% of samples contained cells that meet both the morphological and immunocytochemical criteria for CTC. In 32.6% of samples, partially degenerated pancytokeratin negative cells with morphological features of tumor cells were observed. In 65.1% of samples, CTCs were not found. In conclusion, our results demonstrate that morphologically intact tumor cells can be isolated using MACS technology. However, morphologically intact tumor cells were not detected in the clinical part of the study. At present, MACS technology does not appear suitable for use in a clinical cytopathology laboratory.
Identifiants
pubmed: 33042837
doi: 10.3389/fonc.2020.554554
pmc: PMC7522616
doi:
Types de publication
Journal Article
Langues
eng
Pagination
554554Informations de copyright
Copyright © 2020 Lozar, Jesenko, Kloboves Prevodnik, Cemazar, Hosta, Jericevic, Nolde and Grasic Kuhar.
Références
J Oncol. 2010;2010:861341
pubmed: 20111743
Cytometry. 1990;11(2):231-8
pubmed: 1690625
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
Cancer Lett. 2007 Aug 18;253(2):180-204
pubmed: 17314005
Arch Pathol Lab Med. 2009 Sep;133(9):1468-71
pubmed: 19722757
Cancer Cytopathol. 2015 Dec;123(12):696-706
pubmed: 26671736
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Curr Breast Cancer Rep. 2014 Sep;6(3):146-153
pubmed: 25431637
PLoS One. 2019 Feb 27;14(2):e0212221
pubmed: 30811434
Oncogene. 2016 Mar 10;35(10):1216-24
pubmed: 26050619
Clin Cancer Res. 2010 May 1;16(9):2634-45
pubmed: 20406831
BJU Int. 2017 Nov;120(5B):E30-E44
pubmed: 27539393
Int J Cancer. 2003 Dec 20;107(6):984-90
pubmed: 14601059
Front Oncol. 2015 Jul 20;5:155
pubmed: 26258068
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Natl Cancer Inst. 2018 Jun 1;110(6):560-567
pubmed: 29659933
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Semin Cancer Biol. 2012 Oct;22(5-6):396-403
pubmed: 22554795
Sci Rep. 2017 Mar 24;7:43464
pubmed: 28337998
J Am Coll Surg. 2016 Jul;223(1):20-9
pubmed: 27049782
Cytotherapy. 1999;1(5):377-88
pubmed: 20426539
J Natl Cancer Inst. 2019 Apr 1;111(4):380-387
pubmed: 30312434
Clin Cancer Res. 2017 Sep 15;23(18):5384-5393
pubmed: 28679772
BMC Cancer. 2016 Jul 07;16:401
pubmed: 27387743
Breast Cancer Res. 2012 Oct 22;14(5):R133
pubmed: 23088337
Adv Exp Med Biol. 2017;994:205-228
pubmed: 28560676
Lancet Oncol. 2012 Jul;13(7):688-95
pubmed: 22677156
Cancers (Basel). 2019 Apr 05;11(4):
pubmed: 30959764
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
pubmed: 16857794
Cancer. 2008 Nov 1;113(9):2422-30
pubmed: 18785255
RSC Adv. 2014;9:4334-4342
pubmed: 25614802
Clin Cancer Res. 2015 Jun 15;21(12):2771-9
pubmed: 25779948
Ann Oncol. 2013 Aug;24(8):2057-61
pubmed: 23676420
BMC Cancer. 2015 Mar 30;15:202
pubmed: 25880692
Diagnostics (Basel). 2015 Oct 29;5(4):428-74
pubmed: 26854164
J Pathol. 1998 Aug;185(4):427-34
pubmed: 9828843
Genes Dev. 2017 Sep 15;31(18):1827-1840
pubmed: 29051388
J Circ Biomark. 2018 Jun 24;7:1849454418782617
pubmed: 30013673
PLoS One. 2015 Dec 22;10(12):e0144535
pubmed: 26695635
Oncology. 2003;64(2):160-5
pubmed: 12566914
Cytotherapy. 2005;7(2):171-85
pubmed: 16040397
J Clin Oncol. 2005 Mar 1;23(7):1420-30
pubmed: 15735118
Cancer Res. 2009 Apr 1;69(7):2912-8
pubmed: 19339269
PLoS One. 2014 Jan 08;9(1):e85264
pubmed: 24416373
Hum Pathol. 2007 Mar;38(3):514-9
pubmed: 17188328
Clin Cancer Res. 2016 May 15;22(10):2583-93
pubmed: 26733614
Ann Oncol. 2012 Mar;23(3):618-624
pubmed: 21642515
Clin Cancer Res. 2002 May;8(5):1085-91
pubmed: 12006523
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4591-4596
pubmed: 28408395
Cancer Med. 2020 Apr;9(7):2290-2298
pubmed: 32017443
Breast Cancer Res. 2011 Jun 15;13(3):R67
pubmed: 21699723
J Natl Cancer Inst. 2014 May 15;106(5):
pubmed: 24832787
Clin Cancer Res. 2008 Nov 1;14(21):7004-10
pubmed: 18980996
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Chem Soc Rev. 2017 Apr 18;46(8):2038-2056
pubmed: 28393954
J Clin Oncol. 2011 Apr 20;29(12):1556-63
pubmed: 21422424
Clin Cancer Res. 2012 Oct 15;18(20):5701-10
pubmed: 22908097
Cancer Metastasis Rev. 1982;1(3):215-25
pubmed: 6309367
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4589-94
pubmed: 9539782
Int J Breast Cancer. 2013;2013:130470
pubmed: 23762567
Mol Cancer Res. 2011 Aug;9(8):997-1007
pubmed: 21665936
Ann Oncol. 2008 May;19(5):891-7
pubmed: 18056915
Br J Cancer. 2011 Oct 25;105(9):1338-41
pubmed: 21970878
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32644115
J Oncol. 2010;2010:617421
pubmed: 20016752
J Hematother. 1997 Apr;6(2):103-14
pubmed: 9131439